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Aims ATI-2042 (budiodarone) is a chemical analogue of amiodarone with a half life of 7 h. It is electrophysiologically similar
to amiodarone, but may not have metabolic and interaction side effects. The sophisticated electrocardiograph logs of
advanced DDDRP pacemakers were used to monitor the efficacy of ATI-2042. The aim of this study was to deter-
mine the preliminary efficacy and safety of ATI-2042 in patients with paroxsymal atrial fibrillation (PAF) and
pacemakers.
Methods
and results
Six women with AF burden (AFB) between 1 and 50% underwent six sequential 2-week study periods. Patients
received 200 mg bid of ATI-2042 during Period 2 (p2), 400 mg bid during p3, 600 mg bid during p4, 800 mg bid
during p5, and no drug during baseline and washout (p1 and p6). Pacemaker data for the primary outcome
measure AFB were downloaded during each period. Mean AFB decreased between baseline and all doses: AFB at
baseline (SD) was 20.3+ 14.6% and mean AFB at 200 mg bid was 5.2 + 4.2%, at 400 mg bid 5.2+ 5.2%, at
600 mg bid 2.8 + 3.4%, and at 800 mg bid 1.5 + 0.5%. The mean reductions in AFB at all doses of ATI-2042
were statistically significant (P , 0.005). Atrial fibrillation burden increased in washout. Atrial fibrillation episodes
tended to increase with ATI-2042, but this was offset by substantial decreases in episode duration. ATI-2042 was
generally well tolerated.
Conclusion ATI-2042 effectively reduced AFB over all doses studied by reducing mean episode duration. A large-scale study will
be required to confirm this effect.
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Introduction
Paroxysmal atrial fibrillation (PAF) is a common and distressing
arrhythmia. Current anti-arrhythmic drugs (AADs) are only partially
effective at treating this condition, and newer, improved agents
would be desirable. Amiodarone is the most effective AAD for
PAF with an efficacy of preventing recurrence of as high as 60% at
2 years.1 However, it has a suboptimal pharmacokinetic and meta-
bolic profile,2–7 an extremely long half-life (t1
2e
¼ 35–68 days), and
a large volume of distribution (VD ¼ 60–70 L/kg) that contributes
to its slow onset of action and toxicity due to metabolic interactions
and long residence times within tissues.
To address these issues, a rationally designed, novel structural
analogue of amiodarone, ATI-2042, was created for the chronic
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oral treatment of AF. Relative to amiodarone, the ester modifi-
cation of ATI-2042 markedly shortens the half-life of ATI-2042 in
blood and tissues by rendering the drug susceptible to rapid
metabolism by plasma and tissue esterases with a half-life of 7 h
and elimination within hours (Data on file, ARYx Therapeutics).8
The similarity of the chemical structure, however, allows
ATI-2042 to retain the electrophysiological properties of
amiodarone.9
This study was a proof of concept design seeking preliminary
information on the pharmacodynamic effects, safety, and tolerabi-
lity of the investigational drug ATI-2042 at a variety of doses, in
patients with PAF. Patients with advanced DDDRP pacemakers
were selected because of the pacemaker’s sophisticated diagnos-
tics and the ability to record continuously and log asymptomatic
as well as symptomatic episodes.
Methods
Design
The study protocol was approved by the East Sussex Local Ethics
Committee. This was an open-label prospective study of the safety
and efficacy of the investigational drug ATI-2042 in patients with PAF.
Study drug
ATI-2042 (budiodarone) tartrate salt is chemically synthesized at
Ricerca Biosciences (Concord, OH, USA). The tablets are manufac-
tured in Mississauga, Ontario, Canada. All synthesis and manufacturing
is in compliance with the United States (US) Food and Drug Adminis-
tration (FDA) current Good Manufacturing Practice (cGMP)
guidelines.
The molecular structure of this new chemical entity is identical to that
of amiodarone, except for the presence of a sec-butyl acetate side chain
at position 2 of the benzofuran moiety (Figure 1, Morey et al.9). The core
of the molecule is a benzofuranyl ring system, to which an iodinated diio-
dophenyl group, a tertiary amine, and the chiral centre of the molecule,
an (S)-2-butanyl group, are added over the course of the synthesis. The
final drug substance is provided as a tartrate salt.
ATI-2042 is not a prodrug of amiodarone, nor is amiodarone a
metabolite of ATI-2042. The electrophysiological activity of
ATI-2042 in animals includes (i) inhibition comparable with amiodar-
one of sodium, potassium, and calcium ion channels, (ii) increased
left and right atrial refractoriness comparable with amiodarone, (iii)
atrial effects (increased St-A and A-H intervals), (iv) ventricular
effects (increased MAPD90 and QT-interval), and (v) a dose-
dependent decrease in heart rate (HR)9 (Data on file, ARYx Thera-
peutics). The major metabolite (ATI-2000) is electrophysiologically
inactive9 (Data on file, ARYx Therapeutics).
Inclusion criteria
Only post-menopausal or surgically sterile females with a significant
PAF burden and pacemakers were included. The pacemakers had to
have been in situ for at least 1 month prior to the study and have
appropriate arrhythmia diagnostics. In this study, Vitatron pacemakers,
models Selection 9000 or T70 pacemakers, were used. Non-specific
but potentially toxic findings were observed in canine testes during
pre-clinical safety testing. Although this finding was explored further,
it was prudent to commence clinical testing in a population not at
risk for this effect. Hence, the present study was limited to post-
menopausal or surgically sterile females; the use of the drug in males
is being addressed in a subsequent study.
After providing written informed consent, the patients underwent
screening assessments to assess suitability for the study and to
obtain a baseline medical history and examination. The value of this
cohort was that the pacemaker was not inserted for bradycardia but
for the treatment of AF using various prevention pacing and rate
control techniques. The inclusion criteria were as follows: age
18–85 years; AF burden (AFB) of 1–50%; able to have pacemaker anti-
arrhythmic algorithms turned off or remain at a stable setting; stable
warfarin regimen; be generally healthy and free from significant comor-
bid illnesses; and able to understand study requirements.
Exclusion criteria
The exclusion criteria were significant structural heart disease (ejec-
tion fraction ,45% and congestive heart failure); abnormal QTc inter-
val (i.e. .470 ms); an abnormal 12-lead electrocardiogram (ECG);
known hypersensitivity to amiodarone or iodine; chronic treatment
with amiodarone within 3 months; demonstrated lack of efficacy
with amiodarone treatment; treatment with any other investigational
drug within 30 days; treatment with any anti-arrhythmic medication
(exclusive of a stable dose of digoxin or a beta-blocker or calcium
blocker) within five half-lives prior to study entry; major surgery
within 3 months prior to study entry or any surgery within 2 weeks
prior to study entry; or any laboratory assay result that was out of
the normal reference range at screening from a standard battery of
blood chemistry, haematology, and urinalysis tests.
Protocol
After providing written informed consent, patients were enrolled
within 8 weeks of screening. During the study, they were reviewed
on days 1, 2, and 8 of each study period. ATI-2042 was increased on
day 1 of each 2-week study period, following routine bloods for hae-
matology, biochemistry, and coagulation screens. Plasma samples for
pharmacokinetic analysis of ATI-2042 and its metabolites were taken
at steady state at the end of each study period just prior to the first
escalated dose of the subsequent period and within 15 min prior to
the pre-dose ECG for that dose.
Patients were then monitored for at least 3 h continuously post-
dose; this included telemetry, vital signs, and oxygen saturations. Elec-
trocardiograms were taken, and the pacemaker data were downloaded
prior to drug administration on day 8 and day 14 of each study period.
Criteria for drug discontinuation included a fall in systolic blood
pressure (BP) to ,90 mmHg systolic, an increase in BP
.200 mmHg, intolerable side-effects, a change in rhythm that in the
opinion of the investigator constituted a risk to safety, or a QRS
increase .50%. Where possible, ECGs of intrinsic rhythm rather
than ventricular-paced rhythm were obtained, as paced complexes
can be difficult to interpret for QT prolongation. An increase in QT
interval .470 ms for intrinsic and .550 ms for paced beats or an
increase of 30% was considered significant.
Figure 1 Chemical structures of ATI-2042 (budiodarone) and
amiodarone. *Ester bond (see text for details).
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Drug titration
The study consisted of six 2-week periods: a baseline period (p1), four
treatment periods (p2–p5), and a washout period where return to
baseline was observed (p6).
The initial ATI-2042 dosage for all subjects was 200 mg orally bid,
and it was then increased by 200 mg bid for each subsequent study
period. Patients received 200 mg bid of ATI-2042 during period 2,
400 mg bid during period 3, 600 mg bid during period 4 and 800 mg
bid during period 5, and no drug was administered during baseline
and washout periods.
Device characteristics
Selection 9000 and T70 pacemakers (Vitatron, Arnhem, The
Netherlands) are dual-chamber pacemakers with sophisticated and
similar algorithms for AF detection and prevention. Atrial fibrillation
detection is based on atrial rate; atrial tachyarrhythmias are detected
when the median atrial cycle length is less than that programmed for
AT or AF detection. In all patients, atrial fibrillation was detected if
the atrial rate was .200 bpm for six consecutive beats, and its end
logged if the atrial rate dropped below 200 bpm for 10 beats. An
arrhythmia diary of up to 400 episodes and 15 detailed onset
reports (DORs) were recorded with rate profile, interval plots, and
electrograms to confirm diagnosis. Pacemaker anti-arrhythmic algor-
ithms were turned off prior to entry into the baseline period and
remained turned off until after washout.
Data collection
Pacemaker data, for the primary outcome measure AFB, were down-
loaded on days 8 and 14 of each 2-week period to allow up to 800
episodes of AF to be recorded.
Outcome measures
The primary outcome measure, AFB, was defined as the duration of
time the subject’s cardiac rhythm was AF divided by the total time
recorded for that study period, expressed as per cent. The total dur-
ation of time that the rhythm was AF is a function of the number of
PAF episodes and the duration of each episode. Therefore, a reduction
in AFB can occur through reduction in either or both of these vari-
ables. Atrial fibrillation burden was compared with baseline during
the treatment periods. Secondary outcome measures were the
number of AF episodes, the safety of ATI-2042, and the incidence
and severity of adverse events (AEs).
Data analysis
The minimum study interval was 2 weeks; data were acquired from the
pacemaker and averaged to give a final value. Atrial fibrillation burden
is given as the percentage of total storage duration.
Statistical analysis
The sample size for this study was selected empirically. All patients who
received any amount of study medication were included in the efficacy
and safety analysis. Efficacy variables for the study group are described
as mean andstandard deviation for each study period; individual responses
to ATI-2042 are also presented. Due to the small number of subjects,
comparisons of periods 2–6 with baseline were made using estimates
from a mixed-effects regression model. This model had a fixed, categorical
effect of period and a random patient effect to account for correlations
over time. A P-value of ,0.05 was considered significant.
Electrocardiogram parameters (ventricular HR, PR, QRS, QT, QTc
interval) were summarized by baseline, dosing period, and washout
using descriptive statistics. Changes from baseline in ECG values at
day 8 of dosing and day 14 of washout were also summarized. Baseline
values of ECG parameters are defined as the mean of three values
recorded prior to the first dose of ATI-2042.
An AE was defined as any untoward medical occurrence in a study
subject administered a medicinal product (either study drug or mar-
keted product), whether or not the event had a causal relationship
with this product.
Trough concentrations of ATI-2042 and its metabolites (ATI-2000,
ATI-2100, and ATI-2142), measured at pre-dose on day 1 of each of
the four treatment periods and on days 1 and 8 of the washout
period, were summarized by time point. Spearman’s rank correlation
was used to examine the relationship between trough concentrations
of ATI-2042 and AFB.
Levels of pacemaker malsensing of AF or over- and under-sensing
were evaluated by the manual examination of each DOR; this was per-
formed for all patients and or every pacemaker download throughout
the study and confirmed by an independent observer. It is presented as
a percentage of the DORs.
Results
Recruitment
Six females, mean age (SD) 70.8+ 7.1 years with PAF of mean
duration 4.7+ 2.3 years, were recruited from Eastbourne District
General Hospital between March and July 2005. One patient with-
drew in period 3 due to gastric AEs (nausea, flatulence, and loose
stools) and for logistical reasons.
Baseline characteristics
Patients were treated with a mean of 1.8+ 1.0 AADs, range 1–3,
for PAF prior to study entry. Three patients had Vitatron T70
pacemakers and three had Selection 9000s. All patients had echo-
cardiographic assessments prior to the study; mean (SD) left atrial
diameter 3.66+ 0.54 cm and mean fractional shortening
41.4+ 10.7% (Table 1).
Pharmacokinetics
All patients were compliant with study medication. Mean trough levels
of ATI-2042 were 0.0+ 0.0 ng/mL at baseline, 2.4+ 0.9 ng/mL at
200 mg bid, 5.2+ 1.7 ng/mL at 400 mg bid, 13.1+ 5.6 ng/mL at
600 mg bid, and 19.8+ 17.9 ng/mL at 800 mg bid, indicating some
dose proportionality. In washout, trough levels of ATI-2042 were
0.3+ 0.4 ng/mL, and its metabolites were low or undetectable.
There was a trend towards correlation between AFB, AF episodes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Patients’ characteristics
Patient Age LAD (cm) FS (%) No. of
AADs
Arrhythmia
duration (years)
1 71 3.12 39.25 2 8
2 81 4.36 33.88 1 4
3 75 3.05 59.9 1 4
4 72 4.09 34.8 1 7
5 65 3.4 48.18 3 3
6 61 3.95 32.43 3 2
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or averaged sinus rhythm duration, and trough levels of ATI-2042, but
this did not reach statistical significance.
Pacemaker data
A summary of ATI-2042 efficacy measures is shown in Table 2.
Mean AFB at baseline ranged from 4.6 to 45.3%, mean (SD)
20.3+ 14.6%. Absolute values of AFB decreased between base-
line and all doses; mean AFB (SD) at 200 mg bid was
5.2+ 4.2%, at 400 mg bid 5.2 + 5.2%, at 600 mg bid
2.8+ 3.4%, and at 800 mg bid 1.5+ 0.5%. There was a
71.2+ 31.3% relative reduction (RR) in p2 from baseline
(P ¼ 0.0045), 71.7+ 20.6% in p3 (P ¼ 0.0047), 79.9+ 26.4% in
p4 (P ¼ 0.0023), and 86.8+ 9.8% in p5 (P ¼ 0.0013). Atrial fibril-
lation burden increased towards baseline in washout; mean (SD)
11.7+ 14.0%, range 0.8–38.4 (P ¼ 0.1880 compared with base-
line). Individual dose–response curves are shown in Figure 2.
The number of AF episodes increased initially with ATI-2042
and remained elevated in washout (Table 2 and Figure 3). Mean
episode duration (SD) decreased from baseline at 4.8+ 5.2 to
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Table 2 Mean (SD) absolute atrial fibrillation burden, relative reductions (RR), and changes in episode number and
episode duration per study period
p1 p2 p3 p4 p5 p6
N 6 6 6 5 5 6
Dose (bid) of ATI-2042 Baseline 200 mg 400 mg 600 mg 800 mg Washout
AFB (%) 20.4+ 14.6 5.2+ 4.2* 5.2+ 5.2* 2.8+ 3.4* 1.5+ 0.5* 11.7+ 14.0
P-value vs. p1 — 0.0045 0.0047 0.0023 0.0013 0.1880
RR-AFB (%) — 71.2+ 31.3 71.7 + 20.6 79.9+ 26.4 86.8+ 9.8 27.4+ 78.3
Episodes (no.) 19.3+ 22.1 31.4+ 38.0 31.9 + 42.3 41.6+ 66.2 22.1+ 27.8 30.9+ 46.3
Episode duration (hrs) 4.8+ 5.2 1.7+ 2.5* 0.6+ 0.7* 0.1+ 0.2* 0.5+ 0.7* 2.4+ 3.0
Trough PK level (ng/mL) 0.0+ 0.0 2.4+ 0.9 5.2+ 1.7 13.1+ 5.6 19.8+ 17.9 0.3+ 0.4
p1 is baseline, p2 200 mg bid, p3 400 mg bid, p4 600 mg bid, p5 800 mg bid, and p6 is the washout period. *P , 0.05 when compared with p1.
Figure 3 Mean (95% CI) (SD) plot of number of atrial fibrilla-
tion episodes by study period.
Figure 2 Individual plots of atrial fibrillation burden by study period.
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1.7 + 2.5 h in p2, to 0.6 + 0.7 h in p3, to 0.1+ 0.2 h in p4, to
0.5 + 0.7 h in p5 (Figure 4). Mean episode duration increased in
washout to 2.4 + 3.0 h, but did not reach baseline values.
Electrocardiographic effects of ATI-2042
There were no significant changes in HR, QRS, QT, or QTc
between baseline and dosing or washout. There were no clinically
significant changes in overall ECG interpretation. The PR interval
showed a trend towards decreasing: reductions from baseline
were 16.6+ 23.9% at 200 mg bid, 11.4+ 22.6% at 400 mg bid,
27.0+ 32.1% at 600 mg bid, 35.1+ 30.9% at 800 mg bid, and
30.7+ 24.3% at washout. There were no group or individual
trends to QT or QTc prolongation with dosing. One patient exhib-
ited a 30–60 ms change in QTc from baseline at 400 mg bid; this
patient had had a previous atrioventricular (AV) node ablation and
had permanently paced rhythm. A change in the paced QTc
amounted to 15% from baseline. No patient exhibited .30%
change from baseline QT or QTc with dosing, despite the pre-
sence or absence of pacing.
Safety
The drug was generally well tolerated. There were no serious AEs
related to study drug. The number of subjects with AEs was similar
in all groups, and most were of mild severity. The highest number
of AEs was in period 5 (800 mg bid) and the fewest in period 4
(600 mg bid); gastric AEs, including transient nausea, flatulence,
and loose stools, were more prevalent at 800 mg bid, clinically
insignificant biochemical abnormalities at 400 mg bid, and cardiac
AEs (transient palpitations) while taking 200 mg bid of ATI-2042.
There were no cases of proarrhythmia, clinical hypothyroidism,
or hyperthyroidism. Three patients demonstrated dose–responsive
increases in thyroid-stimulating hormone, which were outside the
normal range. The level in one patient increased from 2.53 to
4.82 mU/L (normal range 0.27–4.2), another increased from 3.51
to 9.49 mU/L, and a third increased from 0.68 to 16.12 mU/L.
None was associated with clinical abnormalities, and all returned
towards normal after drug discontinuation in washout. There
were minor fluctuations in free T4 and free T3, which were felt
not to be clinically significant.
Accuracy
A total of 524 DORs were manually overread for accuracy, mean
87+ 69 per patient. A total of 10.9% of the DORs exhibited
under- or over-sensing, and 6.3% of the DORs were undersensed
almost exclusively due to blanking of P waves during AV delay as
opposed to P wave fallout. Over-sensing was entirely due to
farfield R sensing (4.6%) and was present in one patient; this
patient had an excessive inter-electrode distance of 17 mm
on the atrial pacing lead. The mean number of malsensed
DORs/patient was 10+ 12.
Discussion
During anti-arrhythmic drug (AAD) development, establishing
human drug efficacy in phase I to III studies is often hindered by
problems of proarrhythmia and tolerability. In addition, arrhythmic
conditions are challenging to treat and evaluate because of hetero-
geneous temporal patterns of arrhythmia behaviour.
This study was novel in using the sophisticated data logs of pace-
makers to monitor drug efficacy continuously throughout the
study and to record all episodes of AF including those which
were asymptomatic. Patients with refractory PAF who had failed
at least one AAD therapy were included in this study. ATI-2042
was significantly effective in reducing AFB at all doses in this
group of patients. The endpoint of AFB can be affected by a
reduction in the number of episodes of AF, indicating an effect
on AF initiation, or by a reduction in the duration of episodes, indi-
cating an effect on the sustainability of the episodes. In this study,
therapy with ATI-2042 was associated with a mild trend for the
number of episodes to increase with doses up to 600 mg bid,
but this was offset by a substantial shortening of mean AF
episode duration at all doses that reached statistical significance.
The overall effect was a clinically and statistically significant
reduction in AFB.
It was also apparent that the effects of ATI-2042, despite its
short half-life, have a prolonged cardiac effect after discontinuation
of the drug. Even in washout, AF parameters did not completely
return to baseline. Trough levels of ATI-2042 and its metabolite
were low or negligible within days of drug discontinuation,
making drug persistence unlikely. It is difficult to generalize the
effects of ATI-2042 at this stage or to rule out random effects,
but it is possible that even relatively short courses of this drug
may promote atrial reverse-remodelling, which have a carry-over
effect longer than its metabolism.
Overall, the drug was well tolerated. The absence of the electro-
cardiographic changes that were seen in animal testing may be due
to the small sample size and/or the inclusion of patients with prior
AV nodal ablation procedures with paced rhythms. One patient
withdrew due to moderate gastric side effects and logistical
reasons. There were no serious AEs related to study drug and
no cases of proarrhythmia. Minor changes in thyroid function
studies were likely reflective of the iodine content of ATI-2042.
These resolved during continued study drug administration or
Figure 4 Mean (95% CI) (SD) plot of atrial fibrillation episode
duration by study period.
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after discontinuing the study medication. This pattern of thyroid
function study changes is consistent with those reported for amio-
darone.2 These findings require additional evaluation in future
studies.
Paroxsymal atrial fibrillation is a common, distressing arrhythmia,
which is often difficult to treat due to its heterogeneity and the
tendency for AADs with class III action to exhibit reverse-use
dependency. Drugs with multiple classes of action rather than
specific class action, such as amiodarone, are the most efficacious
in treating AF, but many drugs are limited to low-risk patients
because of concerns regarding proarrhythmia. Amiodarone has
been shown to be superior to other AADs in the maintenance
of sinus rhythm post-cardioversion,1,10,11 but it is less effective in
preventing recurrence in PAF than chronic AF.11 It has a pharma-
cokinetic and metabolic profile that contributes to its slow onset
and offset of action and its toxicity. Prescribing class I agents,
such as flecanide and quinidine, tends to be limited to patients
without ischaemic heart disease, who have preserved left ventricu-
lar function. This is due to the observation of increased mortality
of post-myocardial infarction patients in the Cardiac Arrhythmia
Suppression Trial12 and concerns regarding Torsades de Pointes
extending to ‘pure’ class III agents such as dofetilide and ibuti-
lide.13–18 New atrio-selective drugs that prolong atrial refractori-
ness without significant effects on ventricular refractoriness or
the QT interval appear promising, but are early in develop-
ment.19,20 In the present study, ATI-2042 was well tolerated and
effective in reducing AFB, with decreases of at least 70% in AFB
at all doses. Its short half-life, rapid onset and offset, small
volume of distribution, and cytochrome P450-independent elimin-
ation represent attractive drug features of an AAD.
This study used the sophisticated monitoring capacity of pace-
makers to record all episodes of AF and differed from the conven-
tional means of assessing drug efficacy by the ‘time to first
recurrence’ of AF. ‘Time to first recurrence’ is the time taken
for an atrial tachyarrhythmia to recur post-chemical or electrical
cardioversion.1 This measure makes the assumption that AF epi-
sodes are uniformly random, i.e. the risk of having an episode at
any given time is uniform.21– 25 However, recent data from pace-
maker and defibrillator studies suggest a tendency to clustering
of fibrillation episodes with the highest instantaneous risk of AF
being immediately after termination.24 Human arrhythmia patterns
vary between patients and the majority of episodes are asympto-
matic,25– 27 making assessment of drug efficacy in PAF patients
challenging even with frequent study follow-up or trans-telephonic
monitoring. Despite the complexities and heterogeneous nature of
PAF, we propose that pacemaker data logs provide a comprehen-
sive documentation of arrhythmia events. The degree of accuracy
of the pacemaker diagnostics as determined by manual overreading
supports the use of this method to measure AFB. Pacemaker logs
may also monitor for proarrhythmia and can be used with hand-
held activators to correlate symptoms with events.
Study limitations
The small number of subjects enrolled and the limited duration of
exposure to ATI-2042 limit generalization of the study results. The
study was also limited to post-menopausal females, which have in
some studies been identified as a higher responder group to
amiodarone;1 the inclusion of men is to be addressed in a sub-
sequent study.
The use of a novel methodology to document the anti-
arrhythmic effects of ATI-2042 is also a limitation of the study.
The inclusion of a positive comparator arm with a well-
characterized drug such as amiodarone or sotalol would have
strengthened the study design by aiding in the interpretation of
results, but would have made the study more complex to conduct.
Nevertheless, the information from this study is useful in estab-
lishing preliminary electrophysiological effects of ATI-2042 in
patients and in guiding future studies. In order to generalize any
effects of ATI-2042 on AF mechanism and confirm dose effects,
a parallel-design study including a placebo control with a larger
cohort of patients with longer follow-up is required.
Accurate sensing of arrhythmias is a consideration for all
methods of monitoring, particularly in relation to drug efficacy.
In this study, levels of malsensing were low because rigorous
attempts were made to eliminate malsensing at screening.
Sensing can often be optimized with appropriate expertise,
and oversensing can be reduced by the use of short tip-to-ring
electrodes.28– 31
Conclusion
Despite limitations, this study preliminarily suggests that ATI-2042 is
safe, well tolerated and may reduce AFB in patients with PAF. It has
a promising electrophysiological and pharmacokinetic profile that
makes it an attractive alternative to amiodarone. This study provides
support for further clinical trials that evaluate the use of this inves-
tigational drug in an expanded cohort of patients with PAF and sup-
ports the concept of using implanted pacemaker devices to monitor
AAD efficacy. Such a randomized, double-blind, placebo-controlled
clinical trial of ATI-2042 is currently being completed.
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